Pharmacologic Management of Pediatric Paroxysmal Sympathetic Hyperactivity in North America

OBJECTIVE Describe pharmacological management approaches to pediatric paroxysmal sympathetic hyperactivity (PSH) among North American pediatric attending physicians. PARTICIPANTS AND METHODS Cross-sectional web-based survey of pediatric attending physicians conducted from March to August 2023. The questionnaire examined PSH medication utilization and preferences, subspecialty responsibilities for managing PSH, and the influence of patient age on medication selection. Descriptive statistics summarize PSH medication utilization and rank-order preferences. Chi-square analyses examined relationships between physician specialty and medication selection. RESULTS Among 295 respondents (33% palliative care, 23% neurology, 18% complex care, 17% physiatry), considerable heterogeneity in PSH pharmacotherapy approaches was observed. The most used abortive PSH medications were gamma-aminobutyric acid A (GABA-A) agonists (86%), alpha-2 agonists (79%), and opioids (49%). Leading preventive PSH medications included alpha-2 agonists (90%), gabapentinoids (89%), and beta-blockers (66%). Top-ranked medications for abortive management were alpha-2 agonists, GABA-A agonists, and non-opioid analgesics; and gabapentinoids, alpha-2 agonists, and beta-blockers for preventive management. While physiatrists and neurologists were most frequently identified as primary managers of PSH at participants’ home institutions, several other specialties (including multidisciplinary models) were reported as well. We observed significant differences in utilization of alpha-2 agonists, opioids, dopamine agonists, and beta-blockers across subspecialties (all P < .05). Patient age influenced medication selection among 41% of our sample. CONCLUSIONS Pharmacologic management of pediatric PSH currently lacks clinical consensus and varies significantly based on physician subspecialty. Our findings underscore the need for focused research efforts to identify optimal treatment strategies and develop standardized and evidence-based management guidelines.

Authors

Institutions

Publication Details

Journal
Hospital Pediatrics
Published
2026-11-16
DOI
https://doi.org/10.1542/hpeds.2026-009531
Primary Topic
Cerebral Palsy and Movement Disorders
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Pharmacologic Management of Pediatric Paroxysmal Sympathetic Hyperactivity in North America

Hitoshi G. Koshiya, Laura A. Kirkpatrick, Julie Hauer, Justin Yu et al.
Hospital Pediatrics
Cerebral Palsy and Movement Disorders
article

Pharmacologic Management of Pediatric Paroxysmal Sympathetic Hyperactivity in North America

Hitoshi G. Koshiya, Laura A. Kirkpatrick, Julie Hauer, Justin Yu, Alyssa Breaugh-Shoup
article en

Abstract

OBJECTIVE Describe pharmacological management approaches to pediatric paroxysmal sympathetic hyperactivity (PSH) among North American pediatric attending physicians. PARTICIPANTS AND METHODS Cross-sectional web-based survey of pediatric attending physicians conducted from March to August 2023. The questionnaire examined PSH medication utilization and preferences, subspecialty responsibilities for managing PSH, and the influence of patient age on medication selection. Descriptive statistics summarize PSH medication utilization and rank-order preferences. Chi-square analyses examined relationships between physician specialty and medication selection. RESULTS Among 295 respondents (33% palliative care, 23% neurology, 18% complex care, 17% physiatry), considerable heterogeneity in PSH pharmacotherapy approaches was observed. The most used abortive PSH medications were gamma-aminobutyric acid A (GABA-A) agonists (86%), alpha-2 agonists (79%), and opioids (49%). Leading preventive PSH medications included alpha-2 agonists (90%), gabapentinoids (89%), and beta-blockers (66%). Top-ranked medications for abortive management were alpha-2 agonists, GABA-A agonists, and non-opioid analgesics; and gabapentinoids, alpha-2 agonists, and beta-blockers for preventive management. While physiatrists and neurologists were most frequently identified as primary managers of PSH at participants’ home institutions, several other specialties (including multidisciplinary models) were reported as well. We observed significant differences in utilization of alpha-2 agonists, opioids, dopamine agonists, and beta-blockers across subspecialties (all P < .05). Patient age influenced medication selection among 41% of our sample. CONCLUSIONS Pharmacologic management of pediatric PSH currently lacks clinical consensus and varies significantly based on physician subspecialty. Our findings underscore the need for focused research efforts to identify optimal treatment strategies and develop standardized and evidence-based management guidelines.

Hospital Pediatrics
Boston Children's Hospital (US), University of Pittsburgh (US), UPMC Health System (US), Duke Medical Center (US), Children's Hospital of Pittsburgh (US), University of Pittsburgh Medical Center (US)
Cerebral Palsy and Movement Disorders
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon